@article{ATM23145,
author = {Richard J. MacIsaac and Melissa H. Lee and Sybil A. McAuley and Glenn M. Ward and David N. O’Neal},
title = {Empagliflozin as an adjunctive therapy for type 1 diabetes},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 2},
year = {2018},
keywords = {},
abstract = {Long-term complications of type 1 diabetes (T1D) due to exposure to chronic hyperglycaemia, including blindness, amputations, cardiovascular disease and kidney failure, remain a fear for many people living with T1D. Intensive insulin therapy reduces the risk of complications, but the majority of people with T1D fail to achieve recommended glycaemic targets (1-3). Furthermore, long-term intensive insulin therapy is associated with weight gain, a relevant side-effect as a significant proportion of people with T1D are now overweight (4).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/23145}
}